
Entero Healthcare Solutions IPO
- Issue price
- ₹1,258
- Listing price
- ₹1,228.7
- -2.33%
- Current price
- ₹1,968.7
- +56.49%
- Subscribed
- 1.56x
- Issue size
- ₹1,600 Cr
- Listed on
- 16 Feb 2024
IPO timeline
- Opens9 FebFri
- Closes13 FebTue
- Allotment14 FebWed
- Refunds15 FebThu
- Demat credit15 FebThu
- Listing16 FebFri
Issue details
- Price band
- ₹1,195 – ₹1,258 per share
- Issue size
- ₹1,600 Cr
- Fresh issue
- Not available
- Offer for sale
- Not available
- Issue type
- Fresh capital cum OFS
- Face value
- ₹10 per share
- Lot size
- 11 shares
- Minimum investment
- ₹13,838
- Listing on
- BSE, NSE
- Exchange code
- ENTERO · 544122
This issue combines a fresh issue and an offer for sale. The amounts for each part are not available in our data; see the offer document for the split.
Lot size and investment
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 11 | ₹13,838 |
| Retail (Max) | 14 | 154 | ₹1,93,732 |
| S-HNI (Min) | 15 | 165 | ₹2,07,570 |
| B-HNI (Min) | 73 | 803 | ₹10,10,174 |
Reservation
- QIB
- 94,91,256 shares (75.00% of the Offer)
- NII
- 18,98,251 shares (15.00% of the Offer)
- Retail
- 12,65,500 shares (10.00% of the Offer)
- Employee
- 70,237 shares (0.55% of the Offer)
Allotment status
The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).
Check allotment on MUFG Intime India- 1Open the registrar's allotment page and select this IPO from the list.
- 2Enter your PAN, application number or DP / Client ID.
- 3Submit to see the number of shares allotted, if any.
- Basis of allotment
- 14 Feb 2024
- Refunds initiated
- 15 Feb 2024
- Shares credited to demat
- 15 Feb 2024
- Listing
- 16 Feb 2024
Grey market premium (GMP)
- Current GMP
- ₹15
- +1.00%
- Estimated listing price
- ₹1,273
- Issue price ₹1,258
- Highest
- ₹120
- 8 Feb
- Lowest
- ₹15
- 13 Feb
GMP by day (₹ per share)
Day-wise GMP table
| Date | GMP | Premium | Est. listing |
|---|---|---|---|
| 13 Feb 2024 | ₹15 | +1.00% | ₹1,273 |
| 12 Feb 2024 | ₹25 | +2.00% | ₹1,283 |
| 10 Feb 2024 | ₹70 | +6.00% | ₹1,328 |
| 9 Feb 2024 | ₹110 | +9.00% | ₹1,368 |
| 8 Feb 2024 | ₹120 | +10.00% | ₹1,378 |
- Kostak rate
- ₹0
GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.
Subscription status
- QIB2.29x
- NII (HNI)0.22x
- Retail1.38x
- Employee1.33x
Financials
- P/E Ratio
- 129.75
- EPS (₹)
- 9.70
- RoE
- -2.66%
- RoCE
- 6.06%
- RoNW
- -1.86%
- PAT Margin
- 4.69%
- Debt / Equity
- 0.45
- NAV (₹)
- 174.21
Separate pre- and post-issue P/E are not available for this IPO; the P/E shown is as disclosed for the issue.
| Period ended | 30 Sep 2023 | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
|---|---|---|---|---|
| Assets | 1,505.95 | 1,308.73 | 1,125.98 | 833.79 |
| Total Income | 1,898.98 | 3,305.72 | 2,526.55 | 1,783.67 |
| Profit After Tax | 11.64 | -11.10 | -29.44 | -15.35 |
| NET Worth | 660.54 | 597.66 | 563.22 | 487.06 |
| Total Borrowing | 488.68 | 373.52 | 285.03 | 141.70 |
Peer comparison
| Company | Issue size | P/E | RoNW | PAT margin | Subscribed | Listing gain |
|---|---|---|---|---|---|---|
| Entero Healthcare Solutions This IPO | ₹1,600 Cr | 129.75 | -1.86% | 4.69% | 1.56x | -2.33% |
| Symbiotec Pharmalab Mainboard · listed 1 Sep 2026 | ₹1,757 Cr | 56.81 | 9.48% | 12.60% | 71.26x | 0.00% |
| Paras Healthcare Mainboard · listed 28 Oct 2026 | ₹1,450 Cr | 37.72 | 11.83% | 10.38% | 2.23x | +3.90% |
| Indegene Mainboard · listed 13 May 2024 | ₹1,841.76 Cr | 33.53 | 18.23% | 12.62% | 70.3x | +44.91% |
| Akums Drugs & Pharmaceuticals Mainboard · listed 6 Aug 2024 | ₹1,856.74 Cr | 13580 | -0.57% | 0.02% | 63.44x | +6.77% |
| Rubicon Research Mainboard · listed 16 Oct 2025 | ₹1,378 Cr | 46.13 | 29.02% | 10.37% | 109.32x | +27.84% |
| Sagility India Mainboard · listed 12 Nov 2024 | ₹2,106.4 Cr | 61.52 | 0.29% | 11.83% | 3.2x | +3.53% |
Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.
IPO objectives
How Entero Healthcare Solutions plans to use the money raised, as stated in the offer document.
- Repayment/prepayment, in full or part, of certain borrowings availed of by our Company₹142.5 Cr
- Funding of long-term working capital requirements of the Company and its Subsidiaries during Fiscals 2025 and 2026₹480 Cr
- General corporate purposes₹91.7 Cr
- Pursuing inorganic growth initiatives through acquisitions₹237 Cr
About Entero Healthcare Solutions
Entero Healthcare Solutions Limited was incorporated in 2018 with its registered office in Gurgaon, Haryana. As per CRISIL, it is among the top three healthcare products distributors in India by revenue in Financial Year 2022. As per CRISIL, it also achieved the fastest scale-up among Indian healthcare products distributors, reaching Rs 25,000 million of operating income within four years of operations. Its technology-driven platform distributes healthcare products to pharmacies, hospitals and clinics across India. Its promoters are Prabhat Agrawal, Prem Sethi and OrbiMed Asia III Mauritius. The IPO was Rs 1,600 crore, with Rs 1,000.07 crore of fresh issue and Rs 599.93 crore of offer for sale by the promoters and other shareholders. Rs 480.00 crore was planned for working capital, Rs 237.00 crore for acquisitions and Rs 142.50 crore for repaying borrowings.
Strengths
- Total income rose from Rs 1,783.67 crore in FY2021 to Rs 3,305.72 crore in FY2023.
- It turned a profit of Rs 11.64 crore in the six months to 30 September 2023.
- Rs 1,000.07 crore of the issue was fresh capital for working capital, acquisitions and debt.
- It is among the top 3 healthcare products distributors in India by revenue.
- Net worth grew from Rs 487.06 crore on 31 March 2021 to Rs 660.54 crore on 30 September 2023.
Risks
- The company made losses of Rs 15.35 crore in FY2021, Rs 29.44 crore in FY2022 and Rs 11.10 crore in FY2023.
- With a loss in FY2023, the pre-issue P/E was negative, and the market value at Rs 1,258 was about Rs 5,471.40 crore.
- Distribution margins are thin, and growth needs heavy working capital, with Rs 480.00 crore of the issue planned for it.
- Total borrowing rose from Rs 141.70 crore on 31 March 2021 to Rs 488.68 crore on 30 September 2023.
- Promoters held 77.11% before the issue and 52.43% after it.
Promoters and shareholding
Prabhat Agrawal, Prem Sethi and OrbiMed Asia III Mauritius Ltd
- Promoter holding, pre-issue
- 77.11%
- Promoter holding, post-issue
- 52.43%
Anchor investors
Registrar, lead managers and documents
Lead managers
Documents
Entero Healthcare Solutions IPO: common questions
1.When does the Entero Healthcare Solutions IPO open and close?
The Entero Healthcare Solutions IPO opens on 9 Feb 2024 and closes on 13 Feb 2024.
2.What is the price band of the Entero Healthcare Solutions IPO?
The price band is ₹1,195 – ₹1,258 per share, with a lot size of 11 shares and a minimum investment of ₹13,838.
3.What is the size of the Entero Healthcare Solutions IPO?
The issue size is ₹1,600 Cr (Fresh capital cum OFS).
4.What is the GMP of the Entero Healthcare Solutions IPO?
The last reported grey market premium is ₹15 per share as of 13 Feb 2024, 12:00 PM IST. GMP is unofficial and changes frequently.
5.When is the Entero Healthcare Solutions IPO allotment?
The basis of allotment is expected on 14 Feb 2024. Allotment status can be checked with the registrar, MUFG Intime India Private Limited.
6.When will the Entero Healthcare Solutions IPO list?
The shares listed on 16 Feb 2024 on BSE, NSE.
7.Who is the lead manager of the Entero Healthcare Solutions IPO?
The book running lead managers are JM Financial Ltd., SBI Capital Markets Ltd., ICICI Securities, Jefferies India Private Limited, Dam Capital Advisors Ltd, and the registrar is MUFG Intime India Private Limited.
8.What will the money raised in the Entero Healthcare Solutions IPO be used for?
As stated in the offer document, the proceeds are for: Repayment/prepayment, in full or part, of certain borrowings availed of by our Company; Funding of long-term working capital requirements of the Company and its Subsidiaries during Fiscals 2025 and 2026; General corporate purposes; Pursuing inorganic growth initiatives through acquisitions.
9.How can my company launch an IPO like Entero Healthcare Solutions?
Start with an IPO readiness assessment: eligibility for the Main Board, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.
For business owners
Your company could be the next listing
Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.
- Eligibility check against NSE Emerge, BSE SME and Main Board norms
- Indicative valuation and issue size for your business
- A clear timeline from readiness to listing day
Check if your business can list
Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.
Prefer to talk? Call +91 92130 20393